A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors

Inclusion Criteria:

- Participants with confirmed advanced and/or metastatic solid tumor, with at least one
tumor lesion of non-critical location accessible to biopsy who have progressed on the
standard of care therapy

- Locally confirmed CEA expression in tumor tissue (more than [>] 20 percent (%) of
tumor cells staining with at least moderate intensity) or centrally confirmed CEA
expression if no archival tumor tissue and fresh biopsy is collected

- Radiologically measurable and clinically evaluable disease

- Life expectancy of greater than or equal to (>/=) 12 weeks

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1

- All acute toxic effects of any prior radiotherapy, chemotherapy or surgical procedure
must have resolved to Grade neuropathy

- Adequate hematological, liver, and renal function

- Negative serum pregnancy test within 7 days prior to study treatment in premenopausal
women and women
- Participants with Gilbert's syndrome will be eligible for the study. A diagnosis of
Gilbert's syndrome will be based on the exclusion of other diseases based on the
following criteria: (i) unconjugated hyperbilirubinemia noted on several occasions;
(ii) no evidence of hemolysis (normal hemoglobin, reticulocyte count, and Lactate
dehydrogenase); (iii) normal liver function tests; (iv) absence of other diseases
associated with unconjugated hyperbilirubinemia

Exclusion Criteria:

- History or clinical evidence of central nervous system (CNS) primary tumors or
metastases including leptomeningeal metastases unless they have been previously
treated, are asymptomatic and have had no requirement for steroids or enzyme inducing
anticonvulsants in the last 14 days before screening

- Participants with an active second malignancy (other than non-melanoma skin cancer, or
cervical carcinoma in situ). Participants who have a history of malignancy are not
considered to have an active malignancy if they have completed therapy and are
considered by their treating physician to be at less than (<) 30% risk for relapse

- Evidence of significant, uncontrolled concomitant diseases which could affect
compliance with the protocol or interpretation of results, including diabetes
mellitus, history of relevant pulmonary disorders and known autoimmune diseases

- Uncontrolled hypertension (systolic >150 millimeter of mercury [mmHg] and/or diastolic
>100 mmHg), unstable angina, congestive heart failure (CHF) of any New York Heart
Association (NYHA) classification, serious cardiac arrhythmia requiring treatment
(exceptions: atrial fibrillation, paroxysmal supraventricular tachycardia), history of
myocardial infarction within 6 months of enrollment

- Active or uncontrolled infections

- Known infection with human immunodeficiency virus (HIV), seropositive status

- Positive test results for chronic hepatitis B infection (defined as positive Hepatitis
B surface antigen [HBsAg] serology and/or HBcAb status)

- Positive test results for hepatitis C (hepatitis C virus [HCV] antibody serology
testing)

- Any other diseases, metabolic dysfunction, physical examination finding, or clinical
laboratory finding giving reasonable suspicion of a disease or condition that would
contraindicate the use of an investigational drug

- Pregnant or breast-feeding women

- Known hypersensitivity to any of the components of RO6895882

- Concurrent therapy with any other investigational drug

- Regular immunosuppressive therapy (that is, for organ transplantation, chronic
rheumatologic disease)

- Chronic use of steroids (including inhaled) will not be allowed. Concurrent high doses
of systemic corticosteroids. High dose is considered as >20 mg of dexamethasone a day
(or equivalent) for >7 consecutive days

- Radiotherapy within the last 4 weeks before start of study drug treatment with the
exception of limited field palliative radiotherapy for bone pain relief